The ROC curve revealed that when the cut-off value was 2.018, the sensitivity of lncRNA-ANRIL for glioma diagnosis was 61.97% and the specificity was 96.67%; the sensitivity and the specificity of SOX9 for glioma diagnosis were 69.72% and 85.00%, respectively, when the cut-off value was 0.395; and when the cut-off value was 0.388, the combined diagnosis had higher sensitivity than the single diagnosis with lncRNA-ANRIL or SOX9. This evidence concerns the gene CDKN2B-AS1 and central nervous system cancer.